IPM Take
GLP-1 medicines are among the most significant therapeutic breakthroughs in decades. For many patients with obesity, diabetes, cardiovascular disease and kidney disease, they are genuinely life-changing. Yet their rapid adoption is exposing a new policy challenge. Clinicians are increasingly reporting concerns about eating disorders, inappropriate prescribing, body image pressures and psychological effects linked to widespread demand. Healthcare systems have spent years debating who should receive these medicines. The next debate may be how to ensure they are used safely, appropriately and equitably.
Executive Summary
Originally developed for type 2 diabetes and later approved for obesity management, GLP-1 receptor agonists have become one of the most widely discussed medicine classes in healthcare. Their effectiveness has driven unprecedented public demand, fuelled by social media, celebrity endorsements and growing awareness of their health benefits. However, clinicians and eating disorder specialists are increasingly raising concerns about unintended consequences, including misuse among people with eating disorders, extreme dietary restriction, nutritional deficiencies and body image-related harms. As access expands, policymakers may need to consider whether existing prescribing, monitoring and telehealth safeguards remain adequate.
Why it matters
- Policymakers: Expanding access may require stronger safeguards to prevent inappropriate use and unintended harm.
- Regulators: Online prescribing and direct-to-consumer access may create new patient safety challenges.
- Clinicians: Screening for eating disorders and mental health vulnerabilities may become increasingly important.
- Payers: Long-term reimbursement decisions may need to account for both benefits and downstream complications.
- Patients: Balancing access to effective treatment with protection from misuse will become increasingly important.
For many patients, GLP-1 medicines have transformed lives.
People living with obesity, type 2 diabetes, cardiovascular disease and chronic kidney disease frequently describe the medicines as life-changing. They report meaningful weight loss, improved metabolic control and reduced cardiovascular risk. Researchers continue to investigate potential benefits across a growing range of conditions, including addiction, liver disease and cancer prevention.
Yet alongside this success story, another narrative is beginning to emerge.
Clinicians specialising in eating disorders and obesity medicine are increasingly reporting concerns that the rapid expansion of GLP-1 prescribing may be colliding with existing epidemics of body dissatisfaction, disordered eating and weight stigma.
The concern is not that the medicines are ineffective.
The concern is that healthcare systems may have underestimated how these medicines would interact with broader social and psychological pressures surrounding weight.
Reports from treatment centres and eating disorder specialists suggest that some patients are obtaining GLP-1 medicines through online platforms while concealing their true weight, medical history or existing eating disorders. Clinicians describe cases involving severe dietary restriction, relapse of anorexia nervosa and the emergence of problematic eating behaviours following treatment initiation.
Some experts argue that the medications may complicate recovery by suppressing hunger signals that many eating disorder programmes aim to help patients recognise and rebuild. Others warn that aggressive appetite suppression can contribute to undernutrition, muscle loss and social isolation related to eating.
The challenge is amplified by unprecedented public demand.
In many countries, GLP-1 medicines have moved beyond clinical settings and become cultural phenomena. Social media platforms feature weight-loss transformations, celebrity stories and discussions of “food noise” reduction. Demand increasingly extends beyond people with obesity or diabetes to individuals seeking aesthetic weight loss or body image enhancement.
This creates a difficult policy dilemma.
On one hand, restricting access risks denying highly effective treatment to patients with serious metabolic disease. On the other, unregulated expansion may expose vulnerable individuals to unnecessary harm.
The issue is particularly relevant as evidence accumulates that response to GLP-1 medicines varies significantly between individuals. Recent research suggests that approximately one in ten people may carry genetic variants associated with reduced responsiveness to some GLP-1 therapies, highlighting the growing need for more personalised approaches to prescribing.
For policymakers, the implications extend beyond obesity treatment.
Questions are beginning to emerge regarding routine screening for eating disorders before prescribing, monitoring requirements during treatment, telehealth safeguards, online prescribing practices and the role of multidisciplinary support services.
The broader lesson may be that healthcare innovation rarely exists in isolation.
GLP-1 medicines entered healthcare systems as treatments for diabetes and obesity. They are increasingly becoming a test case for how health systems manage the intersection of chronic disease, mental health, digital prescribing and societal attitudes toward weight.
The success of these medicines is no longer in doubt.
The challenge now is ensuring that success does not create a new set of problems that healthcare systems are unprepared to address.
